A 62-year-old woman from Mumbai with a 5-year history of stable angina is currently on atenolol 50 mg once daily and isosorbide mononitrate 60 mg once daily. She reports persistent anginal episodes 2–3 times per week despite good compliance. Her blood pressure is 128/80 mmHg, heart rate 62/min. Coronary angiography shows significant stenosis of the left anterior descending artery suitable for percutaneous coronary intervention (PCI), which she declines. She has no contraindications to additional antianginal therapy. Which of the following is the most appropriate next addition to her regimen?

Explanation

## Clinical Scenario Analysis This patient is on dual antianginal therapy (beta-blocker + long-acting nitrate) and remains symptomatic. She requires a **third agent**. The choice of third agent depends on haemodynamic status and contraindications. ## Triple Therapy in Stable Angina **High-Yield:** When beta-blocker + nitrate fails, the third agent is typically: - **Dihydropyridine calcium channel blocker (amlodipine, nifedipine XR)** — first choice - **Non-dihydropyridine CCB (diltiazem, verapamil)** — if dihydropyridine not tolerated - **Ivabradine** — if heart rate remains elevated - **Nicorandil** — alternative, especially in Asian populations ## Why Amlodipine Is Correct **Key Point:** Amlodipine is the preferred third agent because: 1. It is a **dihydropyridine** (peripheral vasodilator, does NOT slow AV conduction) 2. Safe to combine with beta-blockers (no additive negative inotropic effect) 3. No drug interactions with nitrates 4. Reduces myocardial oxygen demand via afterload reduction 5. Improves coronary blood flow via coronary vasodilation **Clinical Pearl:** In this patient: - Heart rate is 62/min (already controlled by beta-blocker) → no need for rate-limiting CCB - Blood pressure is 128/80 mmHg (well-controlled) → amlodipine's vasodilatory effect is safe - No AV conduction abnormalities evident → no contraindication to any CCB ## Mechanism of Amlodipine in Angina **Mnemonic:** **DIHP = DILATE PERIPHERY, PRESERVE HEART RATE** - Dihydropyridines (amlodipine, nifedipine) → vascular smooth muscle L-type Ca²⁺ channel blockade - Peripheral vasodilation → reduced afterload → reduced myocardial oxygen demand - Coronary vasodilation → improved blood supply - No negative inotropic or chronotropic effects (unlike non-dihydropyridines) ## Comparison Table: Calcium Channel Blockers in Angina | Feature | Amlodipine (DIHP) | Diltiazem (Non-DHP) | Verapamil (Non-DHP) | Nicorandil | |---------|---|---|---|---| | **Peripheral vasodilation** | ✓✓ (strong) | Moderate | Moderate | ✓ | | **AV conduction slowing** | None | ✓ (moderate) | ✓ (strong) | None | | **Negative inotrope** | None | Mild | ✓ (moderate) | None | | **Safe with beta-blocker** | ✓ (preferred) | ⚠ (caution) | ⚠ (caution) | ✓ | | **Heart rate effect** | Reflex ↑ (mild) | ↓ | ↓↓ | Neutral | | **First-line 3rd agent** | ✓ Yes | Only if DHP contraindicated | Only if DHP contraindicated | Alternative | [cite:KD Tripathi 8e Ch 12] ## Why Each Distractor Is Problematic **Diltiazem and Verapamil (Non-dihydropyridines):** - Both slow AV conduction and have negative inotropic effects - When combined with a beta-blocker, risk of: - Severe bradycardia - AV block - Cardiogenic shock (especially verapamil) - Reserved for patients who cannot tolerate dihydropyridines or need rate control - This patient's heart rate is already well-controlled (62/min) → non-DHP CCBs are unnecessary and risky **Nicorandil:** - A potassium channel opener (not a CCB) - Effective antianginal agent, but **not first-line as third agent** - Used when CCBs are contraindicated or in special populations - Risk of ulceration with long-term use (especially oral ulcers, GI ulcers) - In this case, amlodipine is preferred [cite:Harrison 21e Ch 297]